Business
Adia Nutrition Announces Subsidiary Adia Med's Submission of Second Clinical Study for IRB Review Targeting Lower Back Pain with AdiaVita
Winter Park, Florida--(Newsfile Corp. - February 16, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its second clinical study for Institutional Review Board (IRB) review. This pivotal study will evaluate the efficacy of AdiaVita, Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain through
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - February 16, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its second clinical study for Institutional Review Board (IRB) review. This pivotal study will evaluate the efficacy of AdiaVita, Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain through non-invasive intravenous (IV) administration.","length":550,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":973,"url":"https://media.zenfs.com/en/newsfile_64/85d3f4fe8886e480120eeb95407a72f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oW5XjAtV4B0mmI.2.iOXoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2OTg7Y2Y9d2VicA--/https://media.zenfs.com/en/newsfile_64/85d3f4fe8886e480120eeb95407a72f2","width":550,"height":973}},"href":"https://images.newsfilecorp.com/files/10520/283832_img_5218.jpg","hrefExternal":true},{"type":"text","content":"AdiaVita Vial","length":13,"tagName":"p","attribs":{}},{"type":"text","content":"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/283832_img_5218.jpg","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"The single-blind, placebo-controlled trial will randomize approximately 100 participants into two groups: one receiving AdiaVita via IV and the other receiving a placebo. The primary objective is to assess AdiaVita's ability to reduce inflammation and promote repair of damaged tissue in the lower back. The study features a crossover design, where after an initial three-month treatment period, participants in the placebo group will receive AdiaVita for the subsequent phase, enabling within-subject comparisons and extended evaluation of effects.","length":553,"tagName":"p"},{"type":"text","content":"Importantly, unlike conventional treatments that often involve ultrasound-guided injections directly into the affected area, this protocol tests systemic delivery via simple IV infusion. A positive outcome could represent a transformative advancement in lower back pain management, offering patients a less invasive, mor...